The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 25, 2023

Filed:

Apr. 06, 2018
Applicant:

Miltenyi Biotec B.v. & Co. KG, Bergisch Gladbach, DE;

Inventors:

Iris Bürger, Rösrath, DE;

Martin Meyer, Kürten, DE;

Andrzej Dzionek, Overath, DE;

Assignee:

Miltenyi Biotec B.V. & CO. KG, Bergisch Gladbach, DE;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 16/28 (2006.01); A61P 37/06 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2851 (2013.01); A61P 37/06 (2018.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/72 (2013.01); C07K 2317/92 (2013.01);
Abstract

The present invention relates to polypeptides comprising a mutant human IgG, which mutant human IgGis capable of increasing the binding to and activation of immunoreceptor tyrosine-based inhibitory motif (ITIM)-containing FcγRIIb/c (CD32b), but not FcγRIIa (CD32a). More specifically, the invention relates to polypeptides comprising at least one human IgGwith a lysine at position 409 (409K), using the EU index according to Kabat et al., which IgGis capable of binding to human CD32b/c with a statistically significant (p=0.05) higher binding affinity than a wild-type human IgGand than a wild-type human IgG, for use in the prevention and/or treatment of an autoimmune disease or allergy, as further defined in the claims.


Find Patent Forward Citations

Loading…